vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and Sachem Capital Corp. (SACH). Click either name above to swap in a different company.
Sachem Capital Corp. is the larger business by last-quarter revenue ($12.0M vs $9.1M, roughly 1.3× Protalix BioTherapeutics, Inc.). Sachem Capital Corp. runs the higher net margin — 8.3% vs -60.3%, a 68.6% gap on every dollar of revenue. On growth, Sachem Capital Corp. posted the faster year-over-year revenue change (-18.8% vs -49.9%). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -13.4%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Sachem Capital Corp.SACHEarnings & Financial Report
Sachem Head Capital Management is an American value-oriented investment management firm based in New York City, managed by Scott Ferguson.
PLX vs SACH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $12.0M |
| Net Profit | $-5.5M | $997.0K |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | -3.1% |
| Net Margin | -60.3% | 8.3% |
| Revenue YoY | -49.9% | -18.8% |
| Net Profit YoY | -184.8% | 119.7% |
| EPS (diluted) | $-0.06 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | — | ||
| Q3 25 | $17.9M | $12.0M | ||
| Q2 25 | $15.7M | $10.8M | ||
| Q1 25 | $10.1M | $11.4M | ||
| Q4 24 | $18.2M | $10.8M | ||
| Q3 24 | $18.0M | $14.8M | ||
| Q2 24 | $13.5M | $15.1M | ||
| Q1 24 | — | $16.8M |
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $2.4M | $997.0K | ||
| Q2 25 | $164.0K | $1.9M | ||
| Q1 25 | $-3.6M | $904.0K | ||
| Q4 24 | $6.5M | $-36.1M | ||
| Q3 24 | $3.2M | $-5.1M | ||
| Q2 24 | $-2.2M | $-3.1M | ||
| Q1 24 | — | $4.7M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | — | ||
| Q3 25 | 11.9% | -3.1% | ||
| Q2 25 | 7.5% | 9.9% | ||
| Q1 25 | -41.0% | 9.0% | ||
| Q4 24 | 39.6% | -131.1% | ||
| Q3 24 | 22.2% | -32.6% | ||
| Q2 24 | -18.0% | -20.6% | ||
| Q1 24 | — | 25.4% |
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | 8.3% | ||
| Q2 25 | 1.0% | 17.5% | ||
| Q1 25 | -35.8% | 7.9% | ||
| Q4 24 | 35.6% | -335.6% | ||
| Q3 24 | 18.0% | -34.2% | ||
| Q2 24 | -16.4% | -20.2% | ||
| Q1 24 | — | 27.8% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | $0.00 | ||
| Q2 25 | $0.00 | $0.02 | ||
| Q1 25 | $-0.05 | $0.00 | ||
| Q4 24 | $0.10 | $-0.79 | ||
| Q3 24 | $0.03 | $-0.13 | ||
| Q2 24 | $-0.03 | $-0.09 | ||
| Q1 24 | — | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $12.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $175.6M |
| Total Assets | $82.3M | $484.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | — | ||
| Q3 25 | $13.6M | $12.6M | ||
| Q2 25 | $17.9M | $23.5M | ||
| Q1 25 | $19.5M | $25.8M | ||
| Q4 24 | $19.8M | $19.6M | ||
| Q3 24 | $27.4M | $7.4M | ||
| Q2 24 | $23.4M | $12.4M | ||
| Q1 24 | — | $56.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $230.2M | ||
| Q4 24 | — | $230.2M | ||
| Q3 24 | — | $264.7M | ||
| Q2 24 | — | $264.7M | ||
| Q1 24 | — | $288.4M |
| Q4 25 | $48.2M | — | ||
| Q3 25 | $52.9M | $175.6M | ||
| Q2 25 | $49.9M | $177.9M | ||
| Q1 25 | $45.2M | $179.3M | ||
| Q4 24 | $43.2M | $181.7M | ||
| Q3 24 | $32.4M | $220.6M | ||
| Q2 24 | $28.6M | $230.2M | ||
| Q1 24 | — | $237.4M |
| Q4 25 | $82.3M | — | ||
| Q3 25 | $82.3M | $484.4M | ||
| Q2 25 | $78.5M | $501.8M | ||
| Q1 25 | $73.9M | $491.4M | ||
| Q4 24 | $73.4M | $492.0M | ||
| Q3 24 | $61.6M | $555.5M | ||
| Q2 24 | $91.5M | $586.3M | ||
| Q1 24 | — | $626.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.15× | ||
| Q1 24 | — | 1.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $4.9M |
| Free Cash FlowOCF − Capex | $1.6M | — |
| FCF MarginFCF / Revenue | 17.8% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | 4.95× |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-3.7M | $4.9M | ||
| Q2 25 | $-5.2M | $501.0K | ||
| Q1 25 | $-5.1M | $191.0K | ||
| Q4 24 | $4.0M | $12.9M | ||
| Q3 24 | $4.1M | $2.3M | ||
| Q2 24 | $-3.6M | $7.0M | ||
| Q1 24 | — | $4.2M |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q1 24 | — | — |
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | 4.95× | ||
| Q2 25 | -31.91× | 0.27× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SACH
Segment breakdown not available.
